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ABSTRACT
Objective To evaluate the efficacy and relative adverse
effects of tricyclic antidepressants in the treatment of
migraine, tension-type, and mixed headaches.
Design Meta-analysis.
Data sources Medline, Embase, the Cochrane Trials
Registry, and PsycLIT.
Studies reviewed Randomised trials of adults receiving
tricyclics as only treatment for a minimum of four weeks.
Data extraction Frequency of headaches (number of
headache attacks for migraine and number of days with
headache for tension-type headaches), intensity of
headache, and headache index.
Results 37 studies met the inclusion criteria. Tricyclics
significantly reduced the number of days withtension-type
headache and number of headache attacks from migraine
than placebo (average standardised mean difference
−1.29, 95% confidence interval −2.18 to −0.39 and −0.70,
−0.93 to −0.48) but not compared with selective serotonin
reuptakeinhibitors(−0.80, −2.63 to0.02 and −0.20, −0.60
to 0.19). The effect of tricyclics increased with longer
duration of treatment (β=−0.11, 95% confidence interval
−0.63 to −0.15; P<0.0005). Tricyclics were also more likely
to reduce the intensity of headaches by at least 50% than
either placebo (tension-type: relative risk 1.41, 95%
confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to
2.62) or selectiveserotoninreuptakeinhibitors(1.73,1.34
to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely
to cause adverse effects than placebo (1.53, 95%
confidence interval 1.11 to 2.12) and selective serotonin
reuptake inhibitors (2.22, 1.52 to 3.32), including dry
mouth(P<0.0005forboth),drowsiness(P<0.0005forboth),
and weight gain (P<0.001 for both), but did not increase
dropout rates (placebo: 1.22, 0.83 to 1.80, selective
serotonin reuptake inhibitors: 1.16, 0.81 to 2.97).
Conclusions Tricyclic antidepressants are effective in
preventing migraine and tension-type headaches and are
more effective than selective serotonin reuptake
inhibitors, although with greater adverse effects. The
effectiveness of tricyclics seems to increase over time.
INTRODUCTION
Headachesarecommonandcausedistressanddisabil-
ity. The prevalence of migraine headaches ranges
between 8.4% and 18% worldwide.
12 Tension-type
headaches are even more common, occurring in 16-
30% of people worldwide, with 3% having headaches
for more than 180 days a year.
2 Migraine headaches
alone cost the United States $1bn (£0.64bn; €0.75bn)
inmedicalcostsand$13bninlostproductivityayear.
3
Tricyclic antidepressants were first shown to be
effective in preventing headaches in 1964
4 and have
become a standard modality in headache
prevention.
5Basedoncurrentstandardsforpreventive
treatment in the United States, 43% of males and 34%
of females who are candidates for such treatment are
not receiving it.
6 This may result from insufficient
understanding of the magnitude of beneficial effects,
an overestimation of adverse effects, or the presump-
tion that efficacy is only confined to migraine head-
aches. In a previous meta-analysis of antidepressants
for headaches, we found that antidepressants were
effective in preventing headaches, equally for ten-
sion-type headaches and migraine headaches.
7 This
meta-analysis was limited by the relatively small num-
ber of available studies at the time. To expand on our
previous systematic review we assessed the efficacy
and tolerability of tricyclics in reducing the headache
burden among adults with migraine or tension-type
headache. We also compared tricyclics with other
treatment modalities to assess whether the efficacy of
tricyclics varies by type of headache, dose, and dura-
tion of treatment.
METHODS
ThisreportcloselyadherestothePRISMAmethodfor
reportingonsystematicreviews.Wesearched,without
languagerestrictions,Medline(1966-March2010)and
Embase (1974-March 2010) using the search strategy
(antidepressive agents, tricyclic OR antidepressive$
OR tricyclic$ OR amitriptyline OR amoxapine OR
clomipramine OR desipramine OR dibenzepin OR
dothiepin OR doxepin OR imipramine OR lofepra-
mine OR nortriptyline OR opipramol OR protripty-
line OR trimipramine) AND (headache or headache
disorders or headache$ OR migrain$ OR tension$
OR cephalgi$ OR cephalalgi$). We also searched
CRISP and FEDRIP databases for unpublished
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Palliative and Supportive Care Trials Register; the
Cochrane Central Register of Controlled Trials; Psy-
cLIT(1974-2002);andPsycINFO(1974-March2010),
and carried out a review of the bibliographies of all
articles retrieved. The last search date was 25 March
2010. The search was supplemented by searches car-
ried out by medical librarians at our institution as well
as the Cochrane clinical research group.
We included published, randomised clinical trials
that evaluated the efficacy of tricyclic antidepressants
in reducing the frequency or severity of migraine or
tension-type headaches. Treatment groups were
required to receive a tricyclic regularly at any dosing
scheduleasasingleinterventionforatleastfourweeks.
Tricyclics could not be combined with other drugs
with possible prophylactic benefit or effect augmenta-
tion. Comparison groups could receive placebo or a
specified alternative drug or non-drug treatment.
Additional inclusion criteria required studies to
include only adults (>18 years) with migraine or ten-
sion-type headache (frequent episodic or chronic) that
could reasonably be defined on the basis of diagnostic
criteria described in 1988 by the International Head-
ache Society
8 or earlier.
910 We excluded secondary
headaches, such as those related to drug overuse, con-
cussion,orlumbarpuncture.Becausetheclassification
of headache has changed over time, two authors inde-
pendently reviewed each included article’s definition
ofheadacheand,wherepossible,classifieditaccording
to the most recent criteria of the International Head-
ache Society.
8
Study selection and data abstraction
We selected articles for inclusion in two stages. In the
first stage two researchers (PGO’M, KJD) indepen-
dently reviewed titles and abstracts to select full text
articles for retrieval. A priori we decided to include
all articles recommended by either reviewer for full
text retrieval. Agreement was only modest during this
stage (κ=0.66). During the second stage two other
researchers(LS,MD) independently appliedinclusion
and exclusion criteria using standardised forms.
Agreement was good (κ=0.86); during this stage, dis-
agreements were resolved by consensus.
Two authors (WS, JLJ) independently abstracted
data using standardised forms. Data abstracted
includedinformationaboutthestudy(setting,country,
language, inclusion and exclusion criteria), informa-
tion about the intervention (design, characteristics of
treatment, such as dose and duration), characteristics
of the participants (age, sex, ethnicity, assessment of
comorbid psychiatric disease), and treatment related
patient reported outcomes for headache (frequency,
intensity or severity, duration, global improvement
or relief, analgesics used, adverse events). For contin-
uous outcomes we abstracted the number of partici-
pants, the mean, and the variance. We calculated
missingvariancesfromreportedPvalues.
11Fordichot-
omous outcomes we abstracted data into 2×2 tables,
requiring at least 50% clinical improvement in
headache. Studies reporting less than 50% improve-
ment were not abstracted. We assessed article quality
independentlyandinduplicate(DB,JLJ)usingtherisk
of bias assessment tool developed by the Cochrane
collaboration,
12 with good inter-rater agreement
(Cochrane: κ=0.83). Disagreements were resolved by
consensus.
Statistical analysis
Because reported measures for headache varied, a
priori we preferentially abstracted and pooled data
onheadachemeasuresinthisorder:frequencyofhead-
ache, intensity of headache, and headache index, per
the recommendations of the reviewers of our
Cochraneprotocol.Forfrequencyweusedthenumber
of headache attacks for migraines and number of days
with headache for tension-type headaches. Intensity
was abstracted in the scale used by each study; some
studies used visual analogue scales, others used other
continuous measures of intensity. Many studies used a
“headache index” to sum aspects of the burden of
headache, usually derived by multiplying the fre-
quency of the headache by intensity. In addition we
pooled analgesic use. Because of differences in mea-
surement of headache burden between studies, we
pooled standardised differences between studies, a
measure also known as an effect size. By convention,
effect sizes greater than 0.8 are considered as large,
those between 0.6 and 0.8 as moderate, and those
between 0.2 and 0.6 as small.
13
For studies with more than one arm, we pooled the
dataforallarmsintoonegroup;ifthiswasnotpossible
we reduced the sample size for each arm by 50% to
prevent overweighting studies. We pooled data using
the DerSimonian and Laird random effects model.
14
Regardless of headache type, we pooled all studies
with stratified analysis to provide estimates for each
subgroup, and used metaregression to test for differ-
ences between these groups. Heterogeneity was
assessed visually using Galbraith plots
15 and the I
2
statistic.
16 For continuous data (such as headache fre-
quency and index) we used standardised mean differ-
ences (absolute differences divided by the standard
deviation). We calculated the percentage maximum
dose by dividing the maximum dose in each study by
the maximum dose allowed for the study drugs. Qual-
ity assessment was done using a component approach.
In addition we tested the effect of study sponsorship,
use of intention to treat analysis, and whether adher-
encewasassessed.Becauseofthelargenumberofana-
lyses,weusedP=0.01asourthresholdforsignificance.
We assessed for small study effects (publication bias)
using the methods of Peters
17 for dichotomous out-
comesandEggers
18forcontinuousones.Weestimated
the number of unpublished trials using Gleser’s
method
19 and assessed for the potential effects of bias
using both the file drawer test
20 and the trim and fill
method.
21 For the file drawer test we tested how
many studies would be required to make our results
clinically insignificant—that is, an effect size less
than 0.30. We explored the potential source of
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regression.
22 All analyses were done using Stata
(v 11.2).
RESULTS
Overall,1471potentialarticleswereidentified.Onthe
initial screen 443 full text articles were retrieved and
assessed for eligibility (fig 1). Thirty seven studies met
the inclusion criteria
423-58; 13 focused on migraine
headaches,
23242931323436404143505158 17 on tension-type
headaches,
4252628333537-39424445475355-57 six on chronic
mixed headaches (components of migraine and ten-
sion-type headaches),
273046484954 and one on psycho-
genic headaches.
52 Six studies used the 1988 criteria
of the International Headache Society, 11 used the
1962 ad hoc committee criteria, and the remainder
used the most recent criteria. All trials of migraine
headaches would meet the most recent criteria.
Among trials of tension-type headache, one met the
criteria for infrequent episodic headaches, six for fre-
quent episodic headaches, and 15 for chronic head-
ache according to the most recent criteria. The six
trialswithmixedheadacheswereanalysedasmigraine
headaches as they better met the criteria for migraine
headache than for tension-type headache.
Twenty nine of the 37 studies used parallel group
designsandeightcrossoverdesigns.Noneofthecross-
overstudiesprovidedsufficientdatafromwhichtocal-
culate paired within patient results.
42529364348515859All
eight were, however, included as one trial,
25 reported
no carry-over effect, and the remainder had either
more than four weeks of washout
4358 or sufficiently
long treatment durations to minimise carry-over
effects.
364348
A total of 3176 participants were enrolled across the
37 studies (table 1). Studies lasted an average of
10 weeks (range 4-26 weeks). A mean 70 participants
(range 10-554) took part in the studies. Seventy three
per cent of participants were women (range 28-98%);
all but one study
52 had more women than men. The
mean age of participants was 39.6 years. Ten studies
were carried out in the United States; five in Italy;
four in the United Kingdom; three each in Denmark,
Germany, and Turkey; two in Russia; and one each in
Australia, Canada, Egypt, Greece, Hungary, Norway,
and Spain. All but four studies were in English.
23304555
Nine trials were sponsored by industry, and in 16 the
source of funding was not stated.
Among the 37 studies, 20 compared a tricyclic with
placebo. Some studies had more than one comparison
group. A few studies compared tricyclics with other
modalities, including eight with selective serotonin
reuptake inhibitors, three with β blockers, three with
heterocyclics, and one each with buspirone,
47
dihydroergotamine,
27 flunarizine,
30 and ritanserin.
49
One study compared amitriptyline with cognitive
behavioural therapy
37 and one with stress
management,
38 one compared biofeedback with ami-
triptyline and propranolol,
46 three compared amitrip-
tyline with spinal manipulation,
265056 and one
compared amitriptyline and fluvoxamine with trans-
cranial brain electrostimulation.
55
Measures of headache included frequency of head-
ache (19 studies), headache intensity (n=5), and head-
ache index (n=13). All the studies using headache
index used frequency of headache as one component
in the index calculation.
Most studies (n=29) titrated the study drugs. The
maximum allowable daily dose for amitriptyline (30
studies) ranged from 10 mg
30 to 150 mg,
3358 whereas
the four studies of clomipramine ranged from 30 mg
43
to 150 mg.
42 Other maximum daily doses of tricyclics
were opipramol 150 mg,
40 doxepin 100 mg,
48 amitrip-
tylinoxide 90 mg,
4853 and desipramine 150 mg.
57 Peri-
odsofdosetitrationrangedfromnone
2427304549tofour
weeks.
333743535758 The mean pooled doses were ami-
triptyline 80.4 mg (95% confidence interval 70.1 to
90.7, range 25-150), amitriptylinoxide 90 mg (one
study), clomipramine 116 mg (104 to 128, range 30-
150), doxepin 50 mg (n=1), and opipramol 75 mg
(n=1).
Seven studies excluded patients with
depression.
25282935475356 Eleven studies reported the
number of patients at trial entry meeting criteria for
depression, ranging from 21% to 98%. The remaining
studies did not measure or report on depression.
Dropout rates ranged from 0 to 52%. Four studies
had less than 10% losses to follow-up,
28495354 eight
between 10% and 20%,
252637-39414755 nine between
20% and 30%,
232427303642444650 eight between 30% and
40%,
2931-354857andfivemorethan40%.
4043515658Losses
to follow-up could not be determined in three
studies.
4384552Intention to treat analyses were done in
only seven trials.
26334950535456
Quality ratings
Although quality varied among the studies, most had
importantlimitationswithdesignorreporting(table 2).
Records screened: titles or abstracts (n=1471)
Full text articles assessed for eligibility (n=443)
Studies included in qualitative and quantitative synthesis (n=37)
Records identified through
other sources (n=279)
Records identified through
databases (n=1192)
Records excluded (κ=0.66) (n=1028)
Records excluded (κ=0.86) (n=406):
  Not trials (n=24)
  No extractable data (n=3)
  Treatment for addiction (n=19)
  Duplicate report (n=8)
  Paediatric trial (n=4)
  Not tricyclic antidepressants (n=11)
  Compared two tricyclics (n=4)
  Treatment of mental disorder (n=162)
  Pharmacokinetic or safety trial (n=87)
  Treatment of other pain (n=79)
  Methods paper (n=2)
  Not tension-type or migraine headaches (n=3)
Fig 1 | Flow of articles through study
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Study (country) Design, intervention (maximum dose)
Duration of
treatment
(weeks)
Headache
type
No of
participants
(% women) Age (range)
Drop outs
(%) Depression
Amelin 2000
23 (Russia) Parallel 3 arm comparing amitriptyline (25 mg), fluoxetine (20 mg), and
maprotiline (25 mg)
12 Migraine 46 (95) 36 (21-57) 23 Hamilton depression
rating scale
Bank 1994
24 (Hungary) Parallel 2 arm comparing amitriptyline (25 mg) with fluvoxamine (50 mg) 12 Migraine 49 (80) 34 (20-62) 23 NS
Bendtsen 1996
25 (Denmark) Crossover 3 arm comparing amitriptyline (75 mg), citalopram (20 mg), and
placebo
8 Tension 34 (65) 40 (18-60) 15 Excluded
Boline 1995
26 (USA) Parallel 2 arm comparing amitriptyline (30 mg) with spinal manipulation 6 Tension 126 (61) 42 (18-69) 16 NS
Bonuso 1983
27 (Italy) Parallel 2 arm comparing amitriptyline (75 mg) with dihydroergotamine (10 mg) 8 Mixed* 30 (68) NS (18-55) 27 NS
Boz 2003
28 (Turkey) Parallel 2 arm comparing amitriptyline (25 mg) with sertraline (50 mg) 12 Tension 84 (89) 40.4 (19-64) 7 Excluded
Bulut 2004
29 (Turkey) Crossover 2 arm comparing venlafaxine (150 mg) with amitriptyline (75 mg) 24 Migraine 52 (85) 31.9 (16-50) 32 Excluded
Canepari 1985
30 (Italy) Parallel 3 arm comparing amitriptyline (10 mg), flunarizine (10 mg), and placebo 12 Mixed* 42 (98) 36 (15-65) 28 NS
Couch 1974
31 (USA) Parallel 2 arm comparing amitriptyline (100 mg) with placebo 4 Migraine 73 (85) NS (NS) 36 Hamilton depression
rating scale, Zung
depression scale
Couch 1976
32 (USA) Parallel 2 arm comparing amitriptyline (100 mg) with placebo 8 Migraine 100 (84) NS (NS) 38 Hamilton depression
rating scale, Zung
depression scale
Diamond 1971
33 (USA) Parallel 3 arm comparing amitriptyline (60 mg), amitriptyline (150 mg), and
placebo
4 Tension 85 (75) 46 (18-68) 32 Measured
(unspecified)
Dodick 2009
34 (USA) Parallel 2 arm comparing topiramate (100 mg) with amitriptyline (100 mg) 26 Migraine 331 (85) 38.8 (18-70) 40 NS
Gobel 1994
35 (Germany) Parallel 2 arm comparing amitryptiline (75 mg) with placebo 6 Tension 53 (70) 43 (NS) 32 Excluded
Gomersall 1973
36 (UK) Crossover 2 arm comparing amitryptiline (60 mg) with placebo 26 Migraine 20 (75) 42 (21-70) 23 Patients were asked if
they were depressed
Holroyd 1991
37 (USA) Parallel 2 armcomparing amitriptyline (75 mg)with cognitive behavioural therapy 12 Tension 41 (80) 32.3 (19-55) 12 Beck depression
inventory
Holroyd 2001
38 (USA) Parallel 4 arm comparing amitriptyline (100 mg) or nortriptyline (100 mg), stress
management therapy, amitriptyline or nortriptyline plus stress management
therapy, and placebo
24 Tension 203 (76) 37 (NS) 12 NS
Indaco 1988
39 (Italy) Parallel 2 arm comparing amitriptyline (50 mg) with placebo 12 Tension 31 (52) 60.4 (41-70) 14 Zung depression scale
Jacobs 1972
40 (UK) Parallel 2 arm comparing opipramol (150 mg) with placebo 12 Migraine 27 (78) 42 (23-67) 43 NS
Keskinbora
41 2008 (Turkey) Parallel 3 arm comparing amitriptyline (150 mg), topiramate (200 mg), and
combination of these two drugs
12 Migraine 63 (67) 37 (NS) 16 Beck depression
inventory
Lance 1964
4 (Australia) Crossover 2 arm comparing amitriptyline (75 mg) with placebo 4 Tension 27 (63) NS (NS) NS NS
Langemark 1990
42 (Denmark) Parallel3armcomparingclomipramine(150mg),mianserin(60mg),andplacebo 6 Tension 82 (NS) 41 (18-69) 28 NS
Langohr 1985
43 (Germany) Crossover5 arm comparingall crossovercombinationsofclomipramine(100mg),
metoprolol (100 mg), and placebo
4 Migraine 36 (67) 44 (24-60) 43 NS
Loldrup 1989
44 (Denmark) Parallel3armcomparingclomipramine(150mg),mianserin(60mg),andplacebo 6 Tension 114 (64) 41 (17-69) 20 Measured
(unspecified)
Martin-Araguz 2003
45 (Spain) Parallel 2 arm comparing amitriptyline (25 mg) with mirtazapine (30 mg) 24 Tension 60 (70) 38 (NS) NS Hamilton depression
rating scale
Mathew 1981
46 (USA) Parallel 8 arm comparing multi-intervention: amitriptyline (75 mg), propranolol
(160 mg), biofeedback, placebo, amitriptyline+propranolol, amitriptyline
+biofeedback, propranolol+biofeedback, and amitriptyline+propranolol
+biofeedback
24 Migraine and
mixed
554 (95) 38 (19-57) 22 Zung depression scale
Mitsikostas 1997
47 (Greece) Parallel 2 arm comparing amitriptyline (50 mg) with buspirone (30 mg) 12 Tension 49 (62) 43 (NS) 16 Hamilton depression
rating scale
Morland 1979
48 (Norway) Crossover 2 arm comparing doxepin (100 mg) with placebo 9 Mixed and
tension
14 (86) NS (20-50) 39 NS
Nappi 1990
49 (Italy) Parallel 2 arm comparing amitriptyline (50 mg) with ritanserin (10 mg) 12 Migraine and
tension
38 (79) 38 (20-50) 0 Hamilton depression
rating scale
Nelson 1998
50 (USA) Parallel 3 arm comparing amitriptyline (100 mg), spinal manipulation, and
amitriptyline+spinal manipulation
8 Migraine 218 (79) 38 (NS) 23 NS
Noone 1980
51 (UK) Crossover 2 arm comparing clomipramine (30 mg) with placebo 8 Migraine 10 (70) NS (18-65) 52 Beck depression
inventory
Okasha 1973
52 (Egypt) Parallel 4 arm comparing amitriptyline (30 mg), doxepin (30 mg), diazepam
(6 mg), and placebo
8 Psychogenic 80 (28) NS (16-60) NS Hamilton depression
rating scale
Pfaffenrath 1994
53 (Germany) Parallel 3 arm comparing amitriptyline (75 mg), amitriptylinoxide (90 mg), and
placebo
12 Tension 197 (56) 38 (18-68) 4.1 Excluded
Rampello 2004
54 (Italy) Parallel 2 arm comparing amitriptyline (50 mg) with citalopram (20 mg) 16 Mixed* 88 (63) 39 (22-64) 0 Hamilton depression
rating scale
Tarosova 2008
55 (Russia) Parallel 3 arm comparing amitriptyline (100 mg), fluvoxamine (100 mg), and
transcranial brain electrostimulation
4 Tension 44 (90) 44 (34-60) 18 Beck depression
inventory
Vernon 2009
56 (Canada) Parallel 4 arm comparing amitriptyline (25 mg), spinal manipulation, sham spinal
manipulation, and amitriptyline+spinal manipulation
14 Tension 20 (80) 34.1 (18-48) 50 Excluded
Walker 1998
57 (UK) Parallel 2 arm comparing desipramine (150 mg) with fluoxetine (40 mg) 12 Tension 25 (81) 35 (19-59) 32 Hamilton depression
rating scale
Ziegler 1987
58 (USA) Crossover 3 arm comparing amitriptyline (150 mg), propranolol (240 mg), and
placebo
4 Migraine 30 (73) 38 (22-57) 44 Hamilton depression
rating scale, Zung
depression scale
NS=not stated.
*Analysed as migraine headache.
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allocation concealment. Although trials were often
reported as double blind, blinding success was
reportedinonlyonetrial
57andwasoftenquestionable,
as treatment groups differed significantly in clinically
recognisable adverse effects.
Headache outcomes
Tricyclics versus placebo
At baseline, participants with migraine averaged 4.7
headaches per month (95% confidence interval 4.3 to
5.1) and those with tension-type headaches 16.9 (15.8
to 18.0), with no difference between tricyclic and pla-
cebo groups (P=0.46). Tricyclics were more effective
than placebo in reducing the burden from both ten-
sion-type headaches (average standardised mean dif-
ference −0.99, 95% confidence interval −1.66 to
−0.32; 11 arms, I
2=93.8%) and migraine headaches
(−1.00, −1.52 to −0.48; 10 arms, I
2=89.4%, fig 2). Tri-
cyclics were equally efficacious between the two head-
ache types. The studies combined yielded an overall
average standardised mean difference for tricyclics of
−0.96 (95% confidence interval −1.39 to −0.53,
I
2=90.1%). Therefore, regardless of the scale used to
measure headaches, patients treated with a tricyclic
experienced nearly 1 standard deviation of improve-
ment, a clinically large effect. Efficacy did not differ
among the different categories of tension-type
Table 2 |Quality of included studies
Study
Drop outs
(%)
Adherence
measured
Adequate
sequence
generation
Allocation
concealment Blinding
Incomplete
data
addressed
Free of
selective
reporting
Free of
other bias
Industry
sponsored
Amelin
23 23 No No Unclear No No Unclear Yes No
Bank
24 23 No Unclear Unclear Unclear No Unclear Yes NS
Bendtsen
25 15 Yes Unclear Unclear Yes No Unclear Yes No
Boline
26 16 Yes Yes Yes No No Unclear No No
Bonuso
27 27 No Unclear Unclear No No No Yes NS
Boz
28 7 Yes Unclear Unclear No Yes Unclear Yes No
Bulut
29 32 No Unclear Unclear Yes No Unclear Yes Yes
Canepari
30 28 Yes No Unclear Yes No Unclear Yes NS
Couch
31 36 No Unclear Unclear Yes No Unclear Yes NS
Diamond
33 6 No Unclear Unclear Yes Yes Unclear Yes NS
Dodick
34 43 No Yes Yes Yes Yes Yes Yes Yes
Gobel
35 32 No Unclear Unclear Yes No Unclear Yes NS
Gomersall
36 23 No Unclear Unclear Unclear No No Yes Yes
Holroyd
1991
37
12 No Unclear Unclear No No Unclear Yes NS
Holroyd
2001
38
12 Yes Yes Unclear No Yes Yes Yes No
Indaco
39 14 Yes Unclear Unclear Yes No Unclear Yes NS
Jacobs
40 43 No Unclear Yes Yes No No Yes Yes
Keskinbora
41 16 Yes Unclear Yes Yes No Yes Yes NS
Lance
4 0 No No Unclear Yes Yes Unclear Yes Yes
Langemark
42 28 No Unclear Unclear Yes No No Yes Yes
Langohr
43 43 No Unclear Unclear Unclear No No Yes Yes
Loldrup
44 20 Yes Unclear Unclear No No No Yes Yes
Martin-
Araguz
45
0 No Unclear Unclear Unclear No Yes Yes NS
Mathew
46 22 No Unclear Unclear No No No Yes NS
Mitsikostas
47 16 No Unclear No No No No Yes NS
Morland
48 39 No Unclear Unclear Unclear No Unclear Yes NS
Nappi
49 0 No Unclear Unclear Unclear Yes Unclear Yes Yes
Nelson
50 23 No Yes Yes No No Unclear Yes No
Noone
51 52 No Yes Yes Unclear No Unclear Yes NS
Okasha
52 0 No Yes Unclear Yes Unclear Unclear Yes NS
Pfaffenrath
53 4.1 Yes Unclear Unclear Unclear Yes Unclear Yes NS
Rampello
54 0 No Unclear Unclear No Yes Unclear Yes NS
Tarosova
55 50 Yes No Unclear Yes No Unclear Yes NS
Vernon
56 50 No Unclear Unclear Yes No Unclear Yes No
Walker
57 32 No Unclear Unclear No No Unclear Yes Yes
Ziegler
58 44 Yes Unclear Unclear Unclear No Unclear Yes No
NS=not stated.
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chronic tension-type, P=0.39).
The numberof headachespermonthamong studies
reporting it were reduced on average by 6.9 for ten-
sion-type headaches (95% confidence interval −21.6
to 7.7, three studies) and 1.4 for migraine headaches
(−3.3 to 0.5, four studies). For both headache types
this beneficial effect increased over time (tension-
type: β=−0.16, 95% confidence interval −0.23 to
−0.10, P<0.0005, migraine: β=−0.09, −0.14 to −0.04,
P=0.001, fig 3). Therefore for every additional week
of treatment with a tricyclic, the number of headaches
were reduced by 0.16 standard deviations. Among
these trials, a range of tricyclic doses was used, with
an average dose that was 50% of the maximum for
the particular tricyclic studied. The effect of doses less
than 50% of the maximum dose was lower than those
with higher doses (average standardised mean differ-
ence −0.73, 95% confidence interval −1.14 to −0.32 v
−0.92, −1.50to −0.34),althoughthe differencewasnot
significant (P=0.34).
Patients taking tricyclics were more likely to experi-
enceatleast50%improvementintheirheadachesthan
those taking placebo for both tension-type headaches
(relative risk 1.41, 95% confidence interval 1.02 to
1.89, four studies, I
2=48.8%) and migraine headaches
(1.80, 1.24 to 2.62, four studies, I
2=0.0%, fig 4). There-
fore,patientstreatedwithtricyclicshada40%and80%
increase in the probability of having 50% improve-
ment in tension-type and migraine headaches,
respectively. Overall, tricyclics improved the likeli-
hood of achieving 50% improvement in headaches
(1.53, 1.16 to 2.01, eight studies, I
2=26.1%).
Tricyclics also reduced the number of doses of
analgesics taken for acute headache pain for both ten-
sion-type headaches (average standardised mean dif-
ference −1.71, 95% confidence interval −3.37 to
−0.05, six studies, I
2=14.5%) and migraine headaches
(−0.94, −1.87 to −0.02, four studies, I
2=32.6%).
Individual adverse effects of tricyclics compared
with placebo were variably reported among the stu-
dies. In seven comparison arms, patients taking tricyc-
lics were more likely to report “any” side effect than
those taking placebo (relative risk 1.89, 95% confi-
dence interval 1.18 to 3.02, I
2=85.9%, fig 5). Among
10 individual adverse effects, only dry mouth (2.34,
1.63 to 3.35, I
2=43.3%) and drowsiness (1.87, 1.25 to
2.70, I
2=55.1%) were statistically more frequent in
patientsreceivingtricyclicsthaninthosereceivingpla-
cebo (table 3). The likelihood of withdrawing due to
adverse effects, however, did not differ among 16 pla-
cebo controlled trials (1.21, 0.80 to 1.82, I
2=74.1%,
fig 5).
Tricyclics versus selective serotonin reuptake inhibitors
In a limited number of trials the effectiveness between
tricyclics and selective serotonin reuptake inhibitors
didnotdifferfortension-typeheadaches(averagestan-
dardisedmeandifference−0.80,95%confidenceinter-
val −1.63 to 0.02, four studies, I
2=89.5%, fig 6) or
Tension-type headaches
  Bendtsen 199625 (amitriptyline 75 mg)
  Diamond 197133 (amitriptyline 60 mg, 150 mg)
  Gobel 199435 (amitriptyline 75 mg)
  Holroyd 200138 (amitriptyline 100 mg)
  Indaco 198839 (amitriptyline 50 mg)
  Langemark 199042 (clomipramine 150 mg)
  Okasha 1973
52 (amitriptyline 30 mg)
  Pfaffenrath 199453 (amitriptylinoxide 90 mg, amitriptyline 75 mg)
Subtotal (I2=95.4%, τ2=1.57)
Migraine headaches
  Couch 1976
32 (amitriptyline 100 mg)
  Gomersall 197336 (amitriptyline 60 mg)
  Jacobs 197240 (opipramol 150 mg)
  Langohr 198543 (clomipramine 100 mg)
  Loldrup 198944 (clomipramine 150 mg)
  Mathew 198146 (amitriptyline 75 mg)
  Morland 197948 (doxepin 100 mg)
  Noone 198051 (clomipramine 30 mg)
  Ziegler 198758 (amitriptyline 150 mg)
Subtotal (I2=25.0%, τ
2=0.22)
Overall (I
2=90.1%, τ
2=0.70)
-2.13 (-2.72 to -1.53)
-0.52 (-1.11 to 0.07)
-0.28 (-0.83 to 0.26)
-4.00 (-4.68 to -3.32)
-2.59 (-3.56 to -1.62)
-0.60 (-1.11 to -0.09)
-0.40 (-1.03 to 0.23)
0.00 (-0.30 to 0.30)
-1.29 (-2.18 to -0.39)
-0.62 (-1.09 to -0.15)
-1.13 (-1.80 to -0.46)
-0.87 (-1.69 to -0.04)
-0.10 (-1.22 to 1.01)
-0.51 (-0.81 to -0.20)
-1.31 (-1.85 to -0.77)
-0.77 (-1.54 to 0.00)
-0.30 (-1.19 to 0.58)
-0.52 (-1.03 to -0.00)
-0.70 (-0.93 to -0.48)
-0.96 (-1.39 to -0.53)
34/18.6 (1.6)
39/0.98 (1)
24/7.9 (6)
53/1.8 (0.2)
15/8.7 (2.9)
28/19 (20)
20/0.8 (3)
133/208 (171)
37/68.5 (58)
20/207 (132)
13/2.9 (1.5)
5/8.85 (7.7)
84/273 (176)
32/2.28 (0.36)
14/462 (65)
10/3 (2)
30/429 (95)
34/21.7 (1.3)
16/1.56 (1.4)
29/9.6 (6)
48/2.6 (0.2)
16/18.9 (4.7)
35/31 (20)
20/2 (3)
64/208 (171)
36/104 (57)
20/356 (132)
12/4.2 (1.5)
8/9.65 (7.7)
87/351 (128)
33/2.72 (0.31)
14/512 (65)
10/3.5 (1.2)
30/511 (202)
-3 -2 -4 -1 0 -5 1 2
Study Standardised mean
difference (95% CI)
Standardised mean
difference (95% CI)
Treatment Control
No/Mean (SD)
6.02
6.04
6.15
5.82
5.06
6.22
5.96
6.60
6.30
5.85
5.45
4.66
6.59
6.16
5.59
5.30
6.21
Weight (%)
(random
effect)
Fig 2 | Effect of tricyclic antidepressants on burden of headache for tension-type and migraine headaches compared with placebo. Trials of mixed and migraine
headaches are combined
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page 6 of 13 BMJ | ONLINE FIRST | bmj.commigraineheadaches(−0.22,−0.75to0.31,fourstudies,
I
2=89.5%). Seven of these trials used amitriptyline and
one used desipramine. The doses used were relatively
low: the maximum dose of amitriptyline averaged
50 mg, ranging from 25 mg to 75 mg; the dose of desi-
pramine was 150 mg. Despite low doses, tricyclics
were more likely than selective serotonin reuptake
inhibitorstoproduceatleast50%improvementinten-
sion-type headaches (relative risk 1.73, 95% confi-
dence interval 1.34 to 2.22, I
2=0.0%, three studies,
fig 7), and migraine headaches (1.72, 1.15 to 2.55,
I
2=9.2%, three studies). Tricyclic arms had higher
rates of several adverse effects such as drowsiness and
drymouth(table 3),althoughtheydidnothavehigher
withdrawalratesfortension-typeheadaches(1.05,0.92
to 1.19, two studies, I
2=0.0%) or migraine headaches
(2.0, 0.90 to 4.47, three studies, I
2=0.0%).
Among three trials, tricyclic arms were more likely
to have “any” side effect than the selective serotonin
reuptake inhibitor arms (2.25, 1.52 to 3.32, I
2=
0.0%).
252857 Specific side effects more common
among tricyclics included abdominal distress (2.34,
1.31 to 4.95, four studies, I
2=6.6%), dizziness (2.52,
0.77 to 8.23, five studies, I
2=63.0%), and dry mouth
(4.88, 2.26 to 10.52, five studies, I
2=67.8%), although
the risk of withdrawing from the study did not differ
(1.16, 0.81 to 2.97, five studies, I
2=19.0%).
Tricyclics versus other drugs
Few studies compared tricyclics with other modalities.
No studies compared β blockers and tricyclics for ten-
sion-type headaches; among three studies of migraine
headaches, tricyclics and β blockers did not differ in
reduction of number of headaches or attacks (average
standardised mean difference 0.90, 95% confidence
interval −0.38 to 2.18, I
2=93.8%) and in two studies
did not differ in the likelihood of experiencing at least
50% reduction in the number of headaches (relative
risk 0.78, 95% confidence interval 0.42 to 1.44,
I
2=0.0%). Three of the studies used amitriptyline and
oneusedclomipramine;theaveragedoseforbothwas
100 mg.
Twostudiesoftension-typeheadachescomparedtri-
cyclicswithbuspirone(amitriptyline50mg)andfound
no differences (buspirone: average standardised mean
difference −1.01, 95% confidence interval −1.83 to
−0.18, I
2=0.00%, table 4). Two studies compared tri-
cyclics (amitriptyline 25 mg, clomipramine 150 mg)
withtetracyclicsandfoundnodifference(averagestan-
dardised mean difference −0.21, −0.65 to 0.22,
Tension-type headaches
  Holroyd 200138 (amitriptyline 100 mg)
  Lance 19644 (amitriptyline 75 mg)
  Langemark 199042 (clomipramine 150 mg)
  Pfaffenrath 199453 (amitriptyline 150 mg)
Subtotal (I2=48.8%, τ
2=0.06)
Migraine headaches
  Canepari 198530 (amitriptyline 10 mg)
  Couch 197431 (amitriptyline 100 mg)
  Couch 197632 (amitriptyline 100 mg)
  Langohr 198543 (clomipramine 100 mg)
Subtotal (I2=0.0%, τ2=0.00)
Overall (I
2=26.1%, τ
2=0.0381)
1.29 (0.74 to 2.27)
5.00 (1.63 to 15.31)
1.18 (0.74 to 1.88)
1.20 (0.78 to 1.86)
1.41 (1.02 to 1.89)
5.25 (0.78 to 35.41)
2.22 (1.04 to 4.76)
1.60 (1.02 to 2.51)
1.35 (0.21 to 8.78)
1.80 (1.24 to 2.62)
1.53 (1.16 to 2.01)
20/53
15/27
16/28
35/133
86/241
7/12
16/37
26/47
2/20
51/116
137/357
14/48
3/27
17/35
28/128
62/238
1/9
7/36
18/52
2/27
28/124
90/362
5 1 0.1 10 35
Study Relative
risk (95% CI)
Relative
risk (95% CI)
Treatment Control
No with events/No in group
26.06
10.30
30.83
32.80
3.84
24.17
68.01
3.99
Weight (%)
(random
effect)
Fig 4 | Likelihood of experiencing at least 50% reduction in tension-type and migraine headaches compared with placebo.
Trials of mixed and migraine headaches are combined
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Fig 3 | Effect of tricyclic antidepressants compared with
placebo over time. SMD=standardised mean difference
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2=32.8%). A single study of tension-type headache
found no difference between low dose amitriptyline
(25 mg) and the serotonin antagonist ritanserin
(−0.49, −1.70 to 0.71). One studyfound that amitripty-
line (75 mg) was better than timed release dihydroer-
gotamine for migraines (−6.57, −8.44 to −4.71). In
addition,twotrialscomparedamitriptyline(maximum
doses 100 mg and 150 mg) with the anticonvulsant
topiramate (0.05, −0.32 to 0.33, I
2=29.2%, table 4)
andone(amitriptyline75mg)withthecalciumchannel
blockerflunarazine(relativerisk 1.60,95% confidence
interval 0.83 to 3.10, table 5) in migraine headaches,
and found no differences.
Tricyclics versus non-drug treatments
No differences were found between spinal manipula-
tion and tricyclics in two studies of tension-type head-
aches (average standardised mean difference −0.25,
95%confidenceinterval−0.59to0.09,I
2=0.0%,table 4)
and one study of migraine headaches (−0.31, −0.69 to
Any adverse effect
  Bendtsen 199625 (amitriptyline 75 mg)
  Diamond 197133 (amitriptyline 60 mg, 150 mg)
  Gomersall 197336 (amitriptyline 60 mg)
  Holroyd 200138 (amitriptyline 100 mg)
  Noone 198051 (clomipramine 30 mg)
  Pfaffenrath 199453 (amitriptyline 75 mg)
  Vernon 2009
56 (amitriptyline 25 mg)
Subtotal (I2=85.9%, τ
2=0.25)
Withdrew from trial
  Bendtsen 1996
25 (amitriptyline 75 mg)
  Canepari 198530 (amitriptyline 10 mg)
  Couch 197632 (amitriptyline 100 mg)
  Diamond 197133 (amitriptyline 60 mg, 150 mg)
  Gobel 199435 (amitriptyline 75 mg)
  Holroyd 200138 (amitriptyline 100 mg)
  Indaco 198839 (amitriptyline 50 mg)
  Jacobs 197240 (opipramol 150 mg)
  Lance 19644 (amitriptyline 75 mg)
  Langemark 199042 (clomipramine 150 mg)
  Loldrup 198944 (clomipramine 150 mg)
  Mathew 198146 (amitriptyline 75 mg)
  Morland 197948 (doxepin 100 mg)
  Noone 198051 (clomipramine 30 mg)
  Pfaffenrath 199453 (amitriptyline 75 mg)
  Vernon 200956 (amitriptyline 25 mg)
Subtotal (I2=74.1%, τ
2=0.44)
2.20 (1.44 to 3.36)
8.29 (1.16 to 59.41)
1.23 (0.83 to 1.82)
2.68 (1.93 to 3.73)
6.00 (0.87 to 41.21)
1.05 (0.93 to 1.18)
1.75 (0.47 to 6.58)
1.89 (1.18 to 3.02)
3.00 (0.13 to 71.51)
0.75 (0.28 to 2.04)
1.13 (0.46 to 2.77)
0.56 (0.30 to 1.02)
1.16 (0.60 to 2.25)
0.37 (0.19 to 0.72)
1.50 (0.28 to 7.93)
1.21 (0.61 to 2.40)
0.82 (0.25 to 2.66)
2.64 (0.91 to 7.66)
6.46 (3.69 to 11.33)
0.97 (0.60 to 1.56)
1.33 (0.34 to 5.30)
1.13 (0.43 to 2.92)
1.30 (0.83 to 2.02)
3.75 (0.22 to 64.56)
1.21 (0.80 to 1.82)
33/40
16/56
16/20
78/97
6/10
111/133
5/10
265/366
1/40
4/16
8/47
14/56
15/44
9/53
3/18
12/26
7/105
10/36
222/306
23/86
4/23
6/16
35/133
2/7
375/1012
15/40
1/29
13/20
27/90
1/10
102/128
2/7
161/324
0/40
9/27
8/53
13/29
10/34
22/48
2/18
8/21
4/49
4/38
11/98
26/94
3/23
5/15
26/128
0/5
151/720
5 1 0.1 10 50 70
Study Relative
risk (95% CI)
Relative
risk (95% CI)
Treatment Control
No with events/No in group
19.37
4.56
19.87
20.66
4.72
22.70
8.13
1.44
6.23
6.73
8.14
7.87
7.84
3.78
7.76
5.45
5.95
8.36
8.73
4.68
6.45
8.86
1.73
Weight (%)
(random
effect)
Fig 5 | Likelihood of adverse effects between tricyclic antidepressants and placebo
Table 3 |Relative risk of adverse effects among tricyclic antidepressants compared with placebo or selective serotonin reuptake inhibitors
Adverse effect Placebo No of studies
Heterogeneity (I2)
%
Selective serotonin
reuptake inhibitors No of studies Heterogeneity (I2)%
Anxiety or irritability 0.44 (0.15 to 1.31) 2 0.0 0.67 (0.23 to 1.91) 2 0.0
Blurred vision 1.05 (0.56 to 1.97) 4 0.0 NR
Constipation or abdominal pain 1.07 (0.61 to 1.86) 7 6.4 2.34 (1.31 to 4.95) 4 6.6
Diaphoresis 1.09 (0.38 to 3.08) 3 73.0 NR NR NR
Dizziness 1.20 (0.77 to 1.86) 7 0.0 2.52 (0.77 to 8.23) 5 63.0
Drowsiness 1.87 (1.25 to 2.70) 10 55.1 2.64 (1.84 to 3.78) 6 17.0
Dry mouth 2.34 (1.63 to 3.35) 10 43.3 4.88 (2.26 to 10.52) 5 67.8
Nausea or vomiting 1.18 (0.42 to 3.31) 4 22.8 0.62 (0.26 to 1.48) 4 57.8
Sleep disturbance 0.64 (0.37 to 1.09) 5 0.0 0.52 (0.17 to 1.58) 3 0.0
Weight gain 1.69 (0.74 to 3.88) 6 49.2 7.45 (0.99 to 56.37) 4 72.0
NR=not reported.
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mum doses of 25 mg, 30 mg, and 100 mg. Tricyclics
were compared with cognitive behavioural therapy in
onestudyoftension-typeheadachesandintwostudies
of migraine headaches, with no differences (tables 4
and 5). All three used amitriptyline at a dose of 75 mg.
Assessment of bias and sensitivity analyses
TheCochranecriteriaseemedtoshowconsiderablerisk
of bias (table 2). On analysis of the components, we
found no difference in effects between studies meeting
or not meeting any Cochrane criteria for bias. We also
found no effect of industry sponsorship or assessment of
adherence on outcomes. We found evidenceofpublica-
tion bias for continuous outcomes (P=0.06) and dichot-
omous outcomes (P=0.04). Estimates based on Gleser’s
method suggested that up to 10 unpublished trials
reporting continuous outcomes and four unpublished
trials reporting dichotomous outcomes could exist.
Rosenthal’s fail safe suggests that 1467 unpublished
trials with continuous outcomes and 691 unpublished
trials with dichotomous outcomes with no effect would
be requiredtoreduce our effectto clinical insignificance
(effect size <0.3). The meta-trim test did not affect the
continuous outcome summary effect, but reduced the
dichotomous outcome from a relative risk of 1.53 (95%
confidence interval 1.16 to 2.01) to one of 1.50 (1.13 to
1.99). Metaregression found no effect of any other vari-
ablesabstractedonsummaryoutcomes,withtheexcep-
tionofstudy duration. Duration explained 32.4% of the
heterogeneityforcontinuousoutcomesand27.3%ofthe
variance for dichotomous outcomes.
DISCUSSION
We found that tricyclic antidepressants substantially
reduced the pain from both migraine and tension-
Tension-type headaches
  Bendtsen 199625 (amitriptyline 75 mg, citalopram 20 mg)
  Boz 200328 (amitriptyline 25 mg, sertraline 50 mg)
  Rampello 200454 (amitriptyline 50 mg, citalopram 20 mg)
  Walker 199857 (desipramine 150 mg, fluoxetine 40 mg)
Subtotal (I2=89.5%, τ
2=0.056)
Migraine headaches
  Amelin 200023 (amitriptyline 25 mg, fluoxetine 20 mg)
  Bank 199424 (amitriptyline 25 mg, fluvoxamine 50 mg)
  Bulut 200429 (amitriptyline 75 mg, venlaxafine 150 mg)
  Rampello 200454 (amitriptyline 50 mg, citalopram 20 mg)
Subtotal (I2=89.5%, τ2=0.412)
Overall (I
2=85.85%, τ
2=0.4069)
-1.93 (-2.51 to -1.35)
-0.16 (-0.59 to 0.27)
-1.07 (-1.52 to -0.62)
0.00 (-0.77 to 0.77)
-0.80  (-1.63 to 0.02)
-0.13 (-0.85 to 0.58)
0.37 (-0.23 to 0.96)
-0.13 (-0.51 to 0.26)
-0.89 (-1.33 to -0.45)
-0.22 (-0.75 to 0.31)
-0.51 (-0.99 to -0.02)
34/18.6 (1.6)
43/13 (5.5)
44/5.6 (3.25)
13/4.2 (2.9)
14/1.4 (1)
20/0.09 (0.06)
52/1.38 (0.98)
44/2.32 (0.86)
34/21.5 (1.4)
41/13.8 (4.2)
44/10.1 (5)
13/4.2 (2.9)
16/1.6 (1.8)
24/0.07 (0.05)
52/1.52 (1.15)
44/3.41 (1.5)
-3 -2 -1 0 1
Study Standardised mean
difference (95% CI)
Standardised mean
difference (95% CI)
Tricyclics SSRI
No/Mean (SD)
24.85
26.30
26.13
22.71
20.74
23.48
28.51
27.27
Weight (%)
(random
effect)
Fig 6 | Comparison of effectiveness of tricyclic antidepressants with selective serotonin reuptake inhibitors for tension-type and migraine headaches. Trials of
mixed and migraine headaches are combined. SSRI=selective serotonin reuptake inhibitor
Tension-type headaches
  Boz 200328 (amitriptyline 25 mg, sertraline 50 mg)
  Rampello 200454 (amitriptyline 50 mg, citalopram 20 mg)
  Tarasova 200855 (amitriptyline 100 mg, fluvoxamine 100 mg)
Subtotal (I2=0.0%, τ
2=0.000)
Migraine headaches
  Amelin 2000
23 (amitriptyline 25 mg, fluoxetine 20 mg)
  Amelin 200023 (maprotiline 25 mg, fluoxetine 20 mg)
  Rampello 200454 (amitriptyline 50 mg, citalopram 20 mg)
Subtotal (I2=9.2%, τ2=0.0162)
Overall (I
2=0.0%, τ2=0.000)
1.64 (1.11 to 2.43)
1.75 (1.22 to 2.50)
2.04 (0.87 to 4.78)
1.73 (1.34 to 2.22)
1.16  (0.43 to 3.14)
1.07 (0.39 to 2.93)
2.06 (1.38 to 3.08)
1.72 (1.15 to 2.55)
1.74 (1.42 to 2.14)
31/43
35/44
7/11
73/98
5/12
5/13
35/44
45/69
118/167
18/41
20/44
5/16
43/101
4.5/12.5
4.5/12.5
17/44
26/69
69/170
0.1 0.5 2 3 4 15
Study Tricyclics SSRI
41.2
50.0
8.8
14.9
14.6
70.5
Weight (%)
(random
effect)
Relative
risk (95% CI)
Relative
risk (95% CI)
No with events/No in group
Fig 7 | Likelihood of experiencing 50% clinical improvement with tricyclics compared with selective serotonin reuptake inhibitors. Trials of mixed and migraine
headaches are combined. SSRI=selective serotonin reuptake inhibitor
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tricyclics experienced about 1 standard deviation of
improvement in headache burden, a clinically large
effect. Patients with tension-type or migraine head-
aches were 40-70% more likely to report at least a
50% improvement in headaches, and patients taking
tricyclics for tension-type headaches used fewer
analgesics. Moreover, the effect seems to increase
over time; patients in the first month of treatment had
less improvement than those treated for six months.
Some adverse effects, particularly dry mouth and
drowsiness, were more likely with tricyclics, although
thisdidnotresultinsignificantlygreaterdropoutrates,
implying a tolerable side effect profile given the bene-
fit. Tricyclics were more effective than selective sero-
tonin reuptake inhibitors in achieving 50% reduction
inheadachesinasmallnumberofcomparativestudies.
Peopletakingtricyclicsweremorelikelytoexperience
dry mouth, drowsiness, and abdominal distress than
those taking selective serotonin reuptake inhibitors,
but were not more likely to withdraw from the study.
In a previous meta-analysis, we found that anti-
depressants reduced headache burden compared with
placebo.
7 This study expands that work in several
important ways. Previously we included only English
language articles and only compared antidepressants
with placebo. This study has a greater number of trials
and includes comparisons with modalities other than
placebo.Thisallowedustoshowthatlongertreatment
improved the efficacy of tricyclics. We were also able
to show that tricyclics are superior to selective seroto-
nin reuptake inhibitors. A recent Cochrane review
found that selective serotonin reuptake inhibitors
were no more effective than placebo for tension-type
headaches. They found some indicators that selective
serotonin reuptake inhibitors were less effective than
tricyclicsformigraines(likelihoodoftaking>5analge-
sic doses per month, number of hours per day with
headache).
60 They concluded that tricyclics were
favoured over selective serotonin reuptake inhibitors,
consistent with the findings reported here.
Itisdifficulttoreachfirmconclusionsontherelative
efficacy of tricyclics compared with other treatment
modalities. There were relatively few studies and
most were underpowered to assess clinical equiva-
lence.
Tricyclics seem equally effective for tension-type,
migraine, and mixed headaches. This is useful infor-
mation for clinicians as differentiating these headache
types may not always be straightforward, especially in
patients with frequent headaches. While this similar
efficacy lends support to the clinical practice of using
the same treatment approaches for recurrent tension,
mixed and migraine headache, it does not address
important underlying theoretical issues. A similarity
in the magnitude of effect does not prove that the
mechanisms underlying these headache types are the
same, that they converge on some final common path-
way, or that the different classes of antidepressants act
through some common mechanism. Neither the
Table 4 |Average standardised mean differences between tricyclic antidepressants and non-placebo treatments for tension-type and migraine headaches
Comparison class
Tension-type headache Migraine headache
Drugs
compared Average SMD (95% CI)
No of
studies
Heteroge-
neity (I2)%
Drugs
compared Average SMD (95% CI)
No of
studies
Heterogeneity
(I2)%
Anticonvulsant —— — — Topiramate 0.05 (−0.32 to 0.33) 2 29.2
β blocker —— — — Propranolol
(×3),
metoprolol
0.90 (−0.38 to 2.18) 4 93.8
Biofeedback —— — — — −0.93 (−2.76 to 0.91) 2 95.5
Buspirone Buspirone −1.01 (−1.83 to −0.18) 2 0 —— — —
Cognitive behavioural therapy — 0.59 (−0.08 to 1.26) 1 —— — — —
Ergotamine —— — — — −6.57 (−8.40 to −4.71) 1 —
Serotonin antagonist Ritanserin −0.49 (−1.70 to 0.71) 1 —— — — —
Spinal manipulation — −0.25 (−0.59 to 0.09) 2 0 — −0.31 (−0.69 to 0.08) 1 —
Tetracyclic Mianserin,
mirtazapine
−0.212 (−0.65 to 0.22) 2 32.8 Maprotiline −0.15 (−0.87 to 0.57) 1 —
Table 5 |Effect of tricyclic antidepressants compared with non-placebo treatments on reduction in headache burden by 50%
Comparison class
Tension-type headache Migraine headache
Drugs
Relative risk (95%
CI) Drugs Relative risk (95% CI)
Anticonvulsant —— Topirimate 0.82 (0.61 to 1.09)*
β blocker —— Metoprolol,
propranolol
0.78 (0.42 to 1.44)*
Calcium channel blocker —— Flunarazine 1.60 (0.83 to 3.10)*
Cognitive behavioural therapy — 1.09 (0.65 to 1.82)* — 0.48 (0.14 to 1.57)*
Tetracyclic Mianserin 1.07 (0.67 to 1.71)* ——
*One study.
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resolve issues of nosology and mechanism.
We also found evidence that the benefit of tricyclics
for headaches increased with longer study duration.
This is consistent with clinical practice and treatment
recommendations suggesting that tricyclics need to be
taken for several months before reaching any conclu-
siononeffectivenessforanygivenpatient.Thescarcity
ofstudieswithlongerdurationisproblematicandcasts
suspicion on the reliability of any conclusions about
the long term efficacy of tricyclics.
Strengths and weaknesses of the study
This study’s strengthsinclude its methodological rigor
and the care taken in study design, data abstraction,
anddataanalysis.However,ourmeta-analysishassev-
eral limitations. Firstly, one of the most important
questions is whether tricyclics are better than other
commonly used prophylactic treatments, such as β
blockers or anticonvulsants. Unfortunately, few trials
compare tricyclics head to head against other modal-
itiesandmanyofthesecomparisonsseemtohavebeen
designedtoputtricyclicsata disadvantage—forexam-
ple, the average dose of tricyclics used in the compar-
ison with selective serotonin reuptake inhibitors is
lower than most clinicians would use in treating head-
aches. More comparative effectiveness trials are
needed.
Secondly, because of the large number of analyses,
caution is required in interpreting our finding of an
association between treatment duration and efficacy.
This analysis should be viewed as exploratory rather
than definitive. Moreover, most trials were relatively
short,particularlysinceheadachestendtobeachronic
problem. The average duration of the trials in our
study was 11 weeks and the longest only 26 weeks;
consequently our timeline was constrained to four to
26 weeks. This finding is consistent with clinical
experience. Many clinicians encourage their patients
to take tricyclics for several months, during which the
doseisslowlyincreased,beforedecidingtotryadiffer-
ent prophylactic agent. This also suggests that treat-
ment trials of longer duration are urgently needed.
Thirdly, it is impossible to differentiate whether
treatment effect was independent of depression. The
relation between depression and physical symptoms
is well described. Patients with depression have more
physical symptoms and report those symptoms as
more severe and disabling than patients without
depression.
6162 Depressed patients experience
improvement in somatic problems when underlying
depression is successfully treated.
63 Patients with
depression have also been found to have more
headaches,
64 although others have argued that this is
a result of chronic underlying pain rather than the
cause of it.
65 The effects of tricyclic antidepressants on
pain syndromes that are considered unrelated to
depression, such as neuropathy, have led investigators
to suggest a direct analgesic effect.
6667 Serotonin has
beenfoundtobeanactiveneurotransmitterinthecen-
tralmodulationofpain,
68sothereisapossibleeffecton
pain mechanisms other than through depression.
Given the short duration and low doses of tricyclics
used for headaches compared with those needed to
treat depression, it seems unlikely that the mechanism
for the success of headache treatment in these trials is
entirely due to the treatment of depression.
A fourthlimitationis the lack ofreportingon conco-
mitantuseofdirect,“asneeded,”drugs.Althoughmost
of the studies included patient diaries on the use of
analgesics during or before the study period, only
four placebo controlled studies and two comparisons
with selective serotonin reuptake inhibitors provide
any results, all showing insignificantly greater reduc-
tion in analgesic use among patients receiving tricyc-
lics. When data are combined across headache types,
there is evidence of reduction in analgesic use. How-
ever,it is possiblethatother trials collectedbut didnot
reporttheirdata;theremaybeabiasagainstpresenting
data suggesting less treatment benefit. Reducing the
need for patient use of analgesics is an important goal
of prophylactic therapy in general, and has the addi-
tional benefit of helping to prevent “rebound” or
drug overuse headaches.
A fifth limitation is that it is impossible to tell from
our data what the optimal dose is for preventing head-
aches. Meta-analysis is limited by the problem of
aggregate data. Optimal dosing is a question that
could be answered only with the availability of patient
level data, given the relatively large number of trials
that have been carried out and the fact that nearly all
trials included titration of tricyclics.
Sixthly,studyqualitywaslowingeneral.Fewstudies
did an intention to treat analysis. This is particularly
worrisome since some trials experienced up to 50%
losses to follow-up. It is easy to imagine that patients
who eitherhad tremendous adverse effectsor had lack
of improvement would be particularly likely to drop
out. We found no difference in effect estimates
between those who did and did not do an intention to
treat analysis, but our sample was relatively small.
Finally, heterogeneity in our results was consider-
able, particularly among people with tension-type
headaches. Study duration explained some, but not
all, of the variance. In addition, there was evidence of
small study effects on our results, also known as pub-
lication bias. Tests to estimate the number of unpub-
lished trials to calculate the number of unpublished
trials necessary to obviate results and tests to “fill in”
missing studies have been criticised for lack of under-
lying theory, poor performance in simulations, and a
tendency to overestimate effects, particularly in the
face of heterogeneity.
69 Since small, negative trials are
less likely to be published, such missing trials would
generallydecreasetheefficacyestimate.Itisimportant
to keep in mind, however, two important potential
sources of confounding. Firstly, the treatment effect is
real. Effective treatments would also seem to have evi-
dence of publication bias. Secondly, tests for publica-
tion bias tend to overestimate risk of bias in the face of
heterogeneity.
69 It is possible, indeed probable, that
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fore possibly an overestimation.
Despite these limitations, our meta-analysis shows
the efficacy of tricyclics in people both with migraine
headacheandwithtension-typeheadache.Thebenefit
seemsmoderatetolarge inmagnitude.Helpful studies
would be those that determine whether particular sub-
groups of patients are more likely to respond to treat-
ment with tricyclics, such as depressed patients or
those with high use of analgesics. It would also be use-
ful to better define more effective treatment regimens,
in terms of target doses, treatment duration, or inter-
actionwithdirectanalgesics.Trialsdirectlycomparing
treatment between tricyclics and other prophylactic
regimens are needed.
This paper is based on a Cochrane review first published in the Cochrane
Library(www.thecochranelibrary.comforinformation).Cochranereviews
are regularly updated as new evidence emerges and in response to
comments and criticisms. The Cochrane Library should be consulted for
the most recent version of the review. The results of a Cochrane review
can be interpreted differently, depending on people’s perspectives and
circumstances.Pleaseconsidertheconclusionspresentedcarefully.They
are the opinions of review authors, and are not necessarily shared by the
Cochrane Collaboration.
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